Shufeng Ma

Shufeng Ma

Auto-generated profile, based on publicly available information

Shufeng Ma

Cancer Research Institute, School of Basic Medical Sciences, State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Key Laboratory of Organ Failure Research (Ministry of Education), Southern Medical University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2022 in BMC Biology
Verified
Journal Article
Open access
PDF file
HHHongxin Huang
Hongxin Huang
GHGuanjie Huang
Guanjie Huang
ZTZhihong Tan
Zhihong Tan
YHYongfei Hu
Yongfei Hu
LSLin Shan
Lin Shan
ZRZhili Rong
Zhili Rong
Background: The CRISPR-Cas12a (formerly Cpf1) system is a versatile gene-editing tool with properties distinct from the broadly used Cas9 system. Features such as recognition of T-rich protospacer-adjacent motif (PAM) and generation of sticky breaks, as well as amenability for multiplex editing in a single crRNA and lower off-target nuclease activity, broaden the targeting scope of available tools and enable more accurate genome editing. However, the widespread use of the nuclease for gene editing, especially in clinical applications, is hindered by insufficient activity and specificity despite previous efforts to improve the system. Currently reported Cas12a variants achieve high activity with a compromise of specificity. Here, we used structure-guided protein engineering to improve both editing efficiency and targeting accuracy of Acidaminococcus sp. Cas12a (AsCas12a) and Lachnospiraceae bacterium Cas12a (LbCas12a). Results: We created new AsCas12a variant termed “AsCas12a-Plus” with increased activity (1.5~2.0-fold improvement) and specificity (reducing off-targets from 29 to 23 and specificity index increased from 92% to 94% with 33 sgRNAs), and this property was retained in multiplex editing and transcriptional activation. When used to disrupt the oncogenic BRAFV600E mutant, AsCas12a-Plus showed less off-target activity while maintaining comparable editing efficiency and BRAFV600E cancer cell killing. By introducing the corresponding substitutions into LbCas12a, we also generated LbCas12a-Plus (activity improved ~1.1-fold and off-targets decreased from 20 to 12 while specificity index increased from 78% to 89% with 15 sgRNAs), suggesting this strategy may be generally applicable across Cas12a orthologs. We compared Cas12a-Plus, other variants described in this study, and the reported enCas12a-HF, enCas12a, and Cas12a-ultra, and found that Cas12a-Plus outperformed other variants with a good balance for enhanced activity and improved specificity. Conclusions: Our discoveries provide alternative AsCas12a and LbCas12a variants with high specificity and activity, which expand the gene-editing toolbox and can be more suitable for clinical applications.

23 June 2023 in Genome Biology
Verified
Journal Article
Open access
PDF file
XZXin Zhang
Xin Zhang
XWXinlong Wang
Xinlong Wang
JLJie Lv
Jie Lv
HHHongxin Huang
Hongxin Huang
JWJiahong Wang
Jiahong Wang
ZRZhili Rong
Zhili Rong
Background: The CRISPR/Cas12a and CRISPR/Cas13d systems are widely used for fundamental research and hold great potential for future clinical applications. However, the short half-life of guide RNAs (gRNAs), particularly free gRNAs without Cas nuclease binding, limits their editing efficiency and durability. Results: Here, we engineer circular free gRNAs (cgRNAs) to increase their stability, and thus availability for Cas12a and Cas13d processing and loading, to boost editing. cgRNAs increases the efficiency of Cas12a-based transcription activators and genomic DNA cleavage by approximately 2.1- to 40.2-fold for single gene editing and 1.7- to 2.1-fold for multiplexed gene editing than their linear counterparts, without compromising specificity, across multiple sites and cell lines. Similarly, the RNA interference efficiency of Cas13d is increased by around 1.8-fold. In in vivo mouse liver, cgRNAs are more potent in activating gene expression and cleaving genomic DNA. Conclusions: CgRNAs enable more efficient programmable DNA and RNA editing for Cas12a and Cas13d with broad applicability for fundamental research and gene therapy.

24 April 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
SMShufeng Ma
Shufeng Ma
KLKaitong Liao
Kaitong Liao
MLMengrao Li
Mengrao Li
XWXinlong Wang
Xinlong Wang
JLJie Lv
Jie Lv
ZRZhili Rong
Zhili Rong
Liquid–liquid phase separation (LLPS) plays a critical role in regulating gene transcription via the formation of transcriptional condensates. However, LLPS has not been reported to be engineered as a tool to activate endogenous gene expression in mammalian cells or in vivo. Here, we developed a droplet-forming CRISPR (clustered regularly interspaced short palindromic repeats) gene activation system (DropCRISPRa) to activate transcription with high efficiency via combining the CRISPR-SunTag system with FETIDR–AD fusion proteins, which contain an N-terminal intrinsically disordered region (IDR) of a FET protein (FUS or TAF15) and a transcription activation domain (AD, VP64/P65/VPR). In this system, the FETIDR–AD fusion protein formed phase separation condensates at the target sites, which could recruit endogenous BRD4 and RNA polymerase II with an S2 phosphorylated C-terminal domain (CTD) to enhance transcription elongation. IDR-FUS9Y>S and IDR-FUSG156E, two mutants with deficient and aberrant phase separation respectively, confirmed that appropriate phase separation was required for efficient gene activation. Further, the DropCRISPRa system was compatible with a broad set of CRISPR-associated (Cas) proteins and ADs, including dLbCas12a, dAsCas12a, dSpCas9 and the miniature dUnCas12f1, and VP64, P65 and VPR. Finally, the DropCRISPRa system could activate target genes in mice. Therefore, this study provides a robust tool to activate gene expression for foundational research and potential therapeutics.

27 January 2021 in Protein & Cell
Verified
Journal Article
Open access
PDF file
JLJun Liu
Jun Liu
JCJunchen Chen
Junchen Chen
YZYadan Zhong
Yadan Zhong
XYXiaoling Yu
Xiaoling Yu
PLPing Lu
Ping Lu
ZRZhili Rong
Zhili Rong

16 July 2021 in The Journal of Gene Medicine
Verified
Journal Article
Closed access
PDF file
SMShufeng Ma
Shufeng Ma
JLJie Lv
Jie Lv
ZFZinan Feng
Zinan Feng
ZRZhili Rong
Zhili Rong
YLYing Lin
Ying Lin

27 September 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
SMShufeng Ma
Shufeng Ma
CKChangyuan Kang
Changyuan Kang
XLXixian Liu
Xixian Liu
LYLichao Yang
Lichao Yang
MLMengyi Li
Mengyi Li
ZYZifeng Yang
Zifeng Yang
Influenza A virus (IAV) commandeers host transcriptional machinery to replicate, but mechanisms remain elusive. CRISPR screen identifies PARP1 as a proviral factor that binds viral NS1. ATAC‑seq reveals IAV drives PARP1‑dependent chromatin remodeling at promoter‑proximal regions (−100 to +300 bp), linking PARP1 to viral RNA synthesis. Mechanistically, NS1 engages PARP1's helical domain (HD), which alone forms large, irregular condensates with low fluidity, acting as a built‑in rheostat. HD deletion confers high droplet mobility, whereas NS1 binding locks PARP1 into a hyper‑condensed, gel‑like state. This phase transition traps Pol II in prolonged pause by enriching pausing factors (SPT5 ‑PLD , NELFA, NELFE) and excluding release factors (SPT5 ‑PRD , AFF4). The paused environment is hijacked for efficient cap‑snatching and viral RNA synthesis. This proviral activity is independent of PARP1's polymerase activity, revealing a non‑canonical mechanism that complements recent reports of PARP1‑mediated antiviral ADP‑ribosylation. Targeting this phase transition, we identify tectochrysin (TEC) and isoferulic acid (IFA), which restore fluidity, reverse pausing, and suppress IAV in mice and lung organoids without toxicity. Our work establishes that NS1 coopts PARP1 phase separation via the HD rheostat to prolong transcriptional pausing, introducing ‘phase transition correction’ as an antiviral paradigm.